Clinical Trials on Neuroblastoma. CNS

Total 4017 results

Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 Neuroblastoma

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of DNA in Blood Samples From Patients With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Recurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of Specimens From Young Patients With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada
National Cancer Institute (NCI)

Completed

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Pain | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma | Neurotoxicity Syndrome

United States
Stephan Grupp MD PhD
Children's Hospital of Philadelphia; University of Pennsylvania; Tmunity Therapeutics

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2)

Refractory Neuroblastoma | High-risk Neuroblastoma | Relapsed Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma | High Risk Neuroblastoma

United States, Canada, Puerto Rico, Australia, New Zealand
Memorial Sloan Kettering Cancer Center

Terminated

Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

Sarcoma | Neuroblastoma | CNS Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

Neuroblastoma | Unspecified Childhood Solid Tumor, Excluding CNS
Nationwide Children's Hospital

Recruiting

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)

Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
Sintetica SA
Sintesi Research Srl

Completed

Observational Study on 2-chloroprocaine Hydrochloride 1% (PASS)

Neurological Complication, in Particular TNS or CES

Belgium
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
University of Virginia
National Cancer Institute (NCI)

Unknown

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States, Canada
Giselle Sholler
Van Andel Research Institute

Completed

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
M.D. Anderson Cancer Center
Elevar Therapeutics

Not yet recruiting

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Metastatic Olfactory Neuroblastoma | Recurrent Olfactory Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable Osteosarcoma

United States, Canada
University of Wisconsin, Madison
National Cancer Institute (NCI); Solving Kids' Cancer; Wade's Army; Midwest Athletes... and other collaborators

Withdrawn

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

Osteosarcoma | Neuroblastoma | Recurrent Neuroblastoma | Relapsed Neuroblastoma

United States
Cancer Research UK

Completed

A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma

Metastatic Neuroblastoma

United Kingdom
Belarusian Research Center for Pediatric Oncology...

Recruiting

DNA Vaccination Against Neuroblastoma

Relapsed Neuroblastoma

Belarus
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
St. Jude Children's Research Hospital
Mayo Clinic

Terminated

A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma

Abdominal Neuroblastoma

United States
Yizhuo Zhang

Recruiting

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood. (CSIIT-Q36)

Neuroblastoma in Children

China
Samsung Medical Center
Ministry of Health, Republic of Korea

Unknown

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

High Risk Neuroblastoma
BeiGene

Completed

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

High-risk Neuroblastoma

China
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
Giselle Sholler
Y-mAbs

Recruiting

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

High-risk Neuroblastoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Terminated

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

Very High Risk Neuroblastoma

Italy, Austria, France, Netherlands, Spain
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
Baylor College of Medicine
New Approaches to Neuroblastoma Therapy Consortium

Completed

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

NEUROBLASTOMA

United States
Samsung Medical Center

Recruiting

Response-based Treatment of High-risk Neuroblastoma

Newly Diagnosed High Risk Neuroblastoma

Korea, Republic of

Clinical Trials on Neuroblastoma. CNS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations